Reduction of GAG storage in MPS II mouse model following implantation on encapsulated recombinant myoblasts

Journal of Gene Medicine

Volumn 7, Issue 11, 2005, Pages 1482-1491

  Friso, Adelaide ^a   Tomanin, Rosella ^a   Alba, Sabrina ^a   Gasparotto, Nicoletta ^a   Puicher, Elisabetta Piller ^a   Fusco, Mariella ^b   Hortelano, Gonzalo ^c   Muenzer, Joseph ^d   Marin, Oriano ^a   Zacchello, Franco ^a   Scarpa, Maurizio ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b Research and Innovation R and I Company   (Italy)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Gene therapy; Hunter syndrome; Lysosomal enzymes; Microcapsules; MPS II mouse model; Somatic cell therapy

Indexed keywords

ALGINIC ACID; DERMATAN; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; IDURONATE 2 SULFATASE; POLYLYSINE;

ALLOGRAFT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ENCAPSULATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME DEFICIENCY; HISTOCHEMISTRY; HUNTER SYNDROME; IMPLANTATION; LYSOSOME; LYSOSOME STORAGE DISEASE; MICROCAPSULE; MOUSE; MYOBLAST; NONHUMAN; PERITONEUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOMATIC GENE THERAPY; TISSUE DISTRIBUTION; TREATMENT OUTCOME; X CHROMOSOME LINKED DISORDER;

ANIMALS; CAPSULES; CELL TRANSPLANTATION; DISEASE MODELS, ANIMAL; GLYCOPROTEINS; GLYCOSAMINOGLYCANS; HUMANS; KIDNEY; LIVER; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUCOPOLYSACCHARIDOSIS II; MYOBLASTS; SPLEEN;

ANIMALIA;

EID: 27944473627     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.790     Document Type: Article

References (51)

1. Altarescu G, Hill S, Wiggs E, et al. The efficacy of enzyme replacement therapy in patients with cronic neuronophatic Gaucher's disease. J Pediatr 2001; 138: 539-547.
2. Perez-Calvo J, Girlado P, Pastores GM, et al. Extended interval between enzyme therapy infusions for adult patients with Gaucher's disease type I. J Postgrad Med 2003; 49: 127-131.
3. Kakkis ED, Muenzer J, Tiller GE, et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 2001; 344: 182-188.
4. Wraith E. Enzyme replacement therapy in mucopolysaccharidosis type I: progress and merging difficulties. J Inher Metab Dis 2001; 24: 245-250.
5. Braun ES, Aronovich EL, Anderson RA, et al. Metabolic correction and cross-correction of mucopolysaccharidosis type II (Hunter syndrome) by retroviral-mediated gene transfer and expression of human iduronate-2-sulfatase. Proc Natl Acad Sci U S A 1993; 90: 11830-11835.
6. Whitley CB. Retroviral-mediated transfer of the iduronate-2-sulfatase gene into lymphocytes for treatment of mild Hunter syndrome (mucopolysaccharidosis type II). Hum Gene Ther 1996; 7: 537-549.
7. Di Francesco C, Cracco C, Tomanin R, et al. In vitro correction of iduronate-2-sulfatase deficiency by adenovirus-mediated gene transfer. Gene Ther 1997; 4: 442-448.
8. Daniele A, Tomanin R, Villani G, et al. Uptake of recombinant iduronate-2-sulfatase into neuronal and glial cells in vitro. Biochim Biophys Acta 2002; 1588: 203-209.
9. Bestor TH. Gene silencing as a threat to the success. J Clin Invest 2000; 105: 409-411.
10. Swindle CS, Klug CA. Mechanisms that regulate silencing of gene expression from retroviral vectors. J Hematother Stem Cell Res 2002; 11: 563-569.
11. Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003; 348: 255-258.
12. Liu Q, Muruve DA. Molecular basis of the inflammatory response to adenovirus vectors. Gene Ther 2003; 10: 935-940.
13. Muruve DA. The innate immune response to adenovirus vectors. Hum Gene Ther 2004; 15: 1157-1166.
14. Tomanin R, Scarpa M. Why do we need new gene therapy viral vectors? Characteristics, limitations and future perspectives of viral vector transduction. Curr Gene Ther 2004; 4: 357-372.
15. Knudson AG Jr, Di Ferrante N, Curtis JE. Effect of leukocyte transfusion in a child with type II mucopolysaccharidosis. Proc Natl Acad Sci USA 1971; 68: 1738-1741.
16. Dean MF, Muir H, Benson PF, et al. Increased breakdown of glycosaminoglycans and appearance of corrective enzyme after skin transplants in Hunter syndrome. Nature 1975; 257: 609-612.
17. Dean MF, Muir H, Benson PF, et al. Enzyme replacement therapy by fibroblast transplantation in a case of Hunter syndrome. Nature 1976; 261: 323-325.
18. Adinolfi M, Akle CA, McColl I. et al. Expression of HLA antigens, beta 2-microglobulin and enzyme by human amniotic epithelial cells. Nature 1982; 295: 325-327.
19. Muenzer J, Neufeld EF, Constantinopoulos G, et al. Attempted enzyme replacement using human amnion membrane implantations in mucopolysaccharidoses. J Inher Metab Dis 1992; 15: 25-37.
20. Chang PL, Nonautologous somatic gene therapy. In Somatic Gene Therapy, Chang PL (ed). CRC Press: Boca Raton, 1995; 203-223.
21. Chang PL. Microcapsules as bio-organs for somatic gene therapy. Ann NY Acad Sci 1997; 831: 461-473.
22. Hughes M, Vassilakos A, Andrews DW, et al. Delivery of a secretable adenosine deaminase through microcapsules - a novel approach to somatic gene therapy. Hum Gene Ther 1994; 5: 1445-1455.
23. Kulseng B, Thu B, Espevik T, Skjak-Braek G. Alginate polylysine microcapsules as immune barrier: permeability of cytokines and immunoglobulins over the capsule membrane. Cell Transplant 1997; 6: 387-394.
24. Potter MA, Hymus S, Stockley T, Chang PL. Suppression of immunological response against a transgene product delivered from microencapsulated cells. Hum Gene Ther 1998; 9: 1275-1282.
25. Read TA, Stensvaag V, Vindenes H, et al. Cells encapsulated in alginate: a potential system for delivery of recombinant proteins to malignant brain tumors. Int J Dev Neurosci 1999; 17: 653-663.
26. Zheng S, Xiao ZX, Pan YL, et al. Continuous release of interleukin 12 from microencapsulated engineered cells for colon cancer therapy. World J Gastroenterol 2003; 9: 951-955.
27. Aebischer P, Pochin NA, Heyd B, et al. Gene therapy for amyotrophic lateral sclerosis (ASL) using a polymer encapsulated xenogenic cell line engineered to secrete hCNTF. Hum Gene Ther 1996; 7: 851-860.
28. Orive G, Hernandez RM, Gascon AR, et al. Survival of different cell lines in alginate-agarose microcapsules. Eur J Pharm 2003; 18: 23-30.
29. Ross CJD, Bastedo L, Maier SA, et al. Treatment of a lysosomal storage disease, mucopolysaccharidosis VII, with microencapsulated recombinant cells. Hum Gene Ther 2000; 11: 2117-2127.
30. Ross CJD, Ralph M, Chang PL. Somatic gene therapy for a neurodegenerative disease using microencapsulated recombinant cells. Exp Neurol 2000; 166: 276-286.
31. Wu Z, Lu Z, Sun AM. Preliminary report on microencapsulated islet transplantation in experimental diabetes mellitus in China. Int J Pancreatol 1988; 3: 91-100.
32. Al-Hendy A, Hortelano G, Tannenbaum GS. Correction of the growth defect in dwarf mice with nonautologous microencapsulated myoblasts: an alternate approach to somatic gene therapy. Hum Gene Ther 1995; 6: 165-175.
33. Al-Hendy A, Hortelano G, Tannenbaum GS, Chang PL. Growth retardation - an unexpected outcome from growth hormone gene therapy in normal mice with microencapsulated myoblasts. Hum Gene Ther 1996; 7: 61-70.
34. Hortelano G, Al-Hendy A, Ofosu FA, Chang PL. Delivery of human factor IX in mice by encapsulated recombinant myoblasts: a novel approach towards allogeneic gene therapy of hemophilia B. Blood 1996; 87: 5095-5103.
35. Hortelano G, Xu N, Vandenberg A, et al. Persistent delivery of factor IX in mice: gene therapy for hemophilia using implantable microcapsules. Hum Gene Ther 1999; 10: 1281-1288.
36. Sun Y, Ma X, Zhou D, et al. Normalization of diabetes in spontaneously diabetic cynomologus monkeys by xenografts of microencapsulated porcine islets without immunosuppression. J Clin Invest 1996; 98: 1417-1422.
37. Van Raamsdonk JM, Ross CJ, Potter MA, et al. Treatment of hemophilia B in mice with nonautologous somatic gene therapeutics. J Lab Clin Med 2002; 139: 35-42.
38. Lin L, Song Y, Song C, et al. Successful xenotransplantation of microencapsulated newborn pig parathyroid cells in the treatment of hypoparathyroidism in rats. Chin Med J (Engl) 2003; 116: 1161-1165.
39. Bjerkvig R, Read TA, Vajkoczy P, et al. Cell therapy using encapsulated cells producing endostatin. Acta Neurochir Suppl 2003; 88: 137-141.
40. Bachoud-Levi AC, Deglon N, Nguyen JP, et al. Neuroprotective gene therapy for Huntington's disease using a polymer encapsulated BHK cell line engineered to secrete human CNTF. Hum Gene Ther 2000; 11: 1723-1729.
41. Muenzer J. Targeted disruption of the mouse iduronate sulfatase gene. 5th Int Symp Mucopolysaccharide and Related Diseases, Vienna, 18-21 March, 1999; 61.
42. Muenzer J, Lamsa JC, Garcia A, et al. Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome): a preliminary report. Acta Paediatr Suppl 2002; 91: 98-99.
43. Montgomery DL, Shiver JW, Leander KR, et al. Heterologous and homologous protection against influenza A by DNA vaccination. DNA Cell Biol 1993; 12: 777-783.
44. Graham FL, van der Eb A. Transformation of rat cells by DNA of human adenovirus 5. Virology 1973; 54: 536-539.
45. Voznyi YV, Keulemans JLM, van Diggelen OP. A fluorogenic assay for the diagnosis of Hunter disease (MPS II). J Inher Metab Dis 2001; 24: 675-680.
46. Tomanin R, Friso A, Alba S, et al. Non-viral transfer approaches for the gene therapy of mucopolysaccharidosis type II (Hunter syndrome). Acta Paediatr Suppl 2002; 439: 100-104.
47. Whitley CB, Ridnour MD, Draper KA, et al. Diagnostic test for mucopolysaccharidosis. I. Direct method for quantifying excessive urinary glycosaminoglycan excretion. Clin Chem 1989; 35: 374-379.
48. De Jong JC, Wevers RA, Liebrand-Van-Sambeek R. Measuring urinary glycosaminoglycans in the presence of protein: an improved screening procedure for mucopolysaccharidosis on dimethylene blue. Clin Chem 1992; 38: 803-807.
49. Vogler C, Sands MS, Levy B, et al. Enzyme replacement with recombinant beta-glucuronidase in murine mucopolysaccharidosis type VII: impact of therapy during the first six weeks of life on subsequent lysosomal storage, growth, and survival. Pediatr Res 1996; 39: 1050-1054.
50. Muenzer J, Fisher A. Advances in the treatment of mucopolysaccharidosis type I. N Engl J Med 2004; 350: 1932-1934.
51. Desnick RJ. Enzyme replacement and enhancement therapies for lysosomal diseases. J Inherit Metab Dis 2004; 27: 385-410.